TRS is a breakthrough immunomodulatory approach, based on a bio-inspired new molecular platform. It has the potential to effectively control a range of autoimmune and inflammatory ocular diseases, potently as steroids, but without the negative side effects.
TRS Mechanism of Action
Today, the only drugs available for treatment of ocular inflammation, target an individual cytoplasmic receptor or secreted protein, but ignore the complexity of the immune system, which results in many limitations of such products. Our synthetic, patent-protected compound (TRS) has a dual-target approach with a unique mechanism of action:
- TRS inhibits the Nf-kB signaling pathway by Toll-Like-Receptor 4 (TLR4). Nf-kB is a transcription factor, whose activation is associated with inflammatory diseases.
- TRS induces a shift of macrophages from a state of pro-inflammatory macrophages (M1) to a state of anti-inflammatory macrophages (M2), thus promoting resolution of inflammation.
Both pathways play key roles in ocular inflammatory diseases.